EP3601302A1 - Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament - Google Patents
Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicamentInfo
- Publication number
- EP3601302A1 EP3601302A1 EP18717242.4A EP18717242A EP3601302A1 EP 3601302 A1 EP3601302 A1 EP 3601302A1 EP 18717242 A EP18717242 A EP 18717242A EP 3601302 A1 EP3601302 A1 EP 3601302A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- atom
- compounds
- alkyl
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title abstract description 16
- 239000000651 prodrug Substances 0.000 title description 6
- 229940002612 prodrug Drugs 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 215
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 24
- 208000015181 infectious disease Diseases 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 150000003212 purines Chemical class 0.000 claims abstract 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 72
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 55
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- 229910052799 carbon Inorganic materials 0.000 claims description 48
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 45
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 44
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 42
- -1 amino acid ester Chemical class 0.000 claims description 36
- 229910052708 sodium Inorganic materials 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000005842 heteroatom Chemical group 0.000 claims description 30
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- 239000011734 sodium Substances 0.000 claims description 27
- 125000004436 sodium atom Chemical group 0.000 claims description 27
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 230000002265 prevention Effects 0.000 claims description 17
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 16
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 16
- 229930024421 Adenine Natural products 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 229960000643 adenine Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 229910052744 lithium Inorganic materials 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 9
- 150000002641 lithium Chemical group 0.000 claims description 9
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 8
- 201000004792 malaria Diseases 0.000 claims description 8
- 229940075420 xanthine Drugs 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 241000223997 Toxoplasma gondii Species 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 241001455947 Babesia divergens Species 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 125000006823 (C1-C6) acyl group Chemical group 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229940083542 sodium Drugs 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 3
- 241001505293 Plasmodium ovale Species 0.000 claims description 3
- 241000223810 Plasmodium vivax Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 241000223846 Babesia canis Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 241000223105 Trypanosoma brucei Species 0.000 claims description 2
- 241000224467 Giardia intestinalis Species 0.000 claims 1
- 241000223821 Plasmodium malariae Species 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229940085435 giardia lamblia Drugs 0.000 claims 1
- 229940118768 plasmodium malariae Drugs 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 144
- 238000005481 NMR spectroscopy Methods 0.000 description 141
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- 239000007787 solid Substances 0.000 description 32
- 239000000460 chlorine Substances 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 238000004679 31P NMR spectroscopy Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 239000012429 reaction media Substances 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 244000045947 parasite Species 0.000 description 14
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 229910052698 phosphorus Inorganic materials 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000012230 colorless oil Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000011574 phosphorus Substances 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000003430 antimalarial agent Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- AVSUMWIDHQEMPD-BYPYZUCNSA-N 2-[(2s)-oxiran-2-yl]ethanol Chemical compound OCC[C@H]1CO1 AVSUMWIDHQEMPD-BYPYZUCNSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 4
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 101900067302 Plasmodium falciparum Hypoxanthine-guanine-xanthine phosphoribosyltransferase Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000078 anti-malarial effect Effects 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229960002743 glutamine Drugs 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000004219 purine nucleobase group Chemical group 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 description 2
- CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 241000223836 Babesia Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101000988835 Escherichia coli (strain K12) Hypoxanthine phosphoribosyltransferase Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000005512 benztetrazolyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002213 purine nucleotide Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- OPKLSCOVJBANHF-VKHMYHEASA-N (2S)-2-(phosphonomethoxy)propanoic acid Chemical compound P(=O)(O)(O)CO[C@H](C(=O)O)C OPKLSCOVJBANHF-VKHMYHEASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- OWIRVNDMYDSKIJ-UHFFFAOYSA-N 2,4-dichloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1Cl OWIRVNDMYDSKIJ-UHFFFAOYSA-N 0.000 description 1
- VSYAHSGHJIPXEU-UHFFFAOYSA-N 2-(2-phosphonoethoxy)propanoic acid Chemical compound P(=O)(O)(O)CCOC(C(=O)O)C VSYAHSGHJIPXEU-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- WKMPTBDYDNUJLF-UHFFFAOYSA-N 2-fluoroadenine Chemical compound NC1=NC(F)=NC2=C1N=CN2 WKMPTBDYDNUJLF-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- HYCKBFLTZGORKA-HNPMAXIBSA-N 3,7-dihydropurin-6-one;1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 HYCKBFLTZGORKA-HNPMAXIBSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- JWVFVDMFVSBWIT-UHFFFAOYSA-N 4-(2-amino-7H-purin-8-yl)butylphosphonic acid Chemical compound P(=O)(O)(O)CCCCC1=NC2=NC(=NC=C2N1)N JWVFVDMFVSBWIT-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
- ZKZBPNGNEQAJSX-REOHCLBHSA-N L-selenocysteine Chemical compound [SeH]C[C@H](N)C(O)=O ZKZBPNGNEQAJSX-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- YAVKWEMBYMOJHH-RXMQYKEDSA-N [(3R)-4-(2,6-diaminopurin-9-yl)-3-hydroxybutyl]phosphonic acid Chemical compound NC1=NC(=C2N=CN(C2=N1)C[C@@H](CCP(=O)(O)O)O)N YAVKWEMBYMOJHH-RXMQYKEDSA-N 0.000 description 1
- YAVKWEMBYMOJHH-YFKPBYRVSA-N [(3S)-4-(2,6-diaminopurin-9-yl)-3-hydroxybutyl]phosphonic acid Chemical compound NC1=NC(=C2N=CN(C2=N1)C[C@H](CCP(=O)(O)O)O)N YAVKWEMBYMOJHH-YFKPBYRVSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SIOVKLKJSOKLIF-UHFFFAOYSA-N bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)OC(C)=N[Si](C)(C)C SIOVKLKJSOKLIF-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UFZNZKGKBWOSJG-UHFFFAOYSA-N purin-2-one Chemical class O=C1N=CC2=NC=NC2=N1 UFZNZKGKBWOSJG-UHFFFAOYSA-N 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000000059 tachyzoite Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- FKLSZDHXGXBRKS-SNVBAGLBSA-N tert-butyl 2,6-diamino-9-[(2R)-3-diethoxyphosphoryl-2-hydroxypropyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)C[C@H](CP(=O)(OCC)OCC)O FKLSZDHXGXBRKS-SNVBAGLBSA-N 0.000 description 1
- JOFCFBRDKHWZSU-LLVKDONJSA-N tert-butyl 2,6-diamino-9-[(2R)-4-diethoxyphosphoryl-2-hydroxybutyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)C[C@@H](CCP(=O)(OCC)OCC)O JOFCFBRDKHWZSU-LLVKDONJSA-N 0.000 description 1
- FKLSZDHXGXBRKS-JTQLQIEISA-N tert-butyl 2,6-diamino-9-[(2S)-3-diethoxyphosphoryl-2-hydroxypropyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)C[C@@H](CP(=O)(OCC)OCC)O FKLSZDHXGXBRKS-JTQLQIEISA-N 0.000 description 1
- JOFCFBRDKHWZSU-NSHDSACASA-N tert-butyl 2,6-diamino-9-[(2S)-4-diethoxyphosphoryl-2-hydroxybutyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)C[C@H](CCP(=O)(OCC)OCC)O JOFCFBRDKHWZSU-NSHDSACASA-N 0.000 description 1
- VFYWTVLTCLMMKQ-SSDOTTSWSA-N tert-butyl 2,6-diamino-9-[2-[(2R)-oxiran-2-yl]ethyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)CC[C@H]1OC1 VFYWTVLTCLMMKQ-SSDOTTSWSA-N 0.000 description 1
- VFYWTVLTCLMMKQ-ZETCQYMHSA-N tert-butyl 2,6-diamino-9-[2-[(2S)-oxiran-2-yl]ethyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)CC[C@@H]1OC1 VFYWTVLTCLMMKQ-ZETCQYMHSA-N 0.000 description 1
- QCFBMXGJWLXEIV-ZCFIWIBFSA-N tert-butyl 2,6-diamino-9-[[(2R)-oxiran-2-yl]methyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)C[C@H]1OC1 QCFBMXGJWLXEIV-ZCFIWIBFSA-N 0.000 description 1
- QCFBMXGJWLXEIV-LURJTMIESA-N tert-butyl 2,6-diamino-9-[[(2S)-oxiran-2-yl]methyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)N)C[C@@H]1OC1 QCFBMXGJWLXEIV-LURJTMIESA-N 0.000 description 1
- GKBDFFRWSKQPDD-LBPRGKRZSA-N tert-butyl 2-amino-9-[(2S)-4-diethoxyphosphoryl-2-hydroxybutyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC=C2N=1)N)C[C@H](CCP(=O)(OCC)OCC)O GKBDFFRWSKQPDD-LBPRGKRZSA-N 0.000 description 1
- PASTYVKQXQSWPK-MRVPVSSYSA-N tert-butyl 2-amino-9-[2-[(2R)-oxiran-2-yl]ethyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC=C2N=1)N)CC[C@H]1OC1 PASTYVKQXQSWPK-MRVPVSSYSA-N 0.000 description 1
- GGBHTODJGZPIPU-SSDOTTSWSA-N tert-butyl 6-amino-2-fluoro-9-[2-[(2R)-oxiran-2-yl]ethyl]purine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)F)CC[C@H]1OC1 GGBHTODJGZPIPU-SSDOTTSWSA-N 0.000 description 1
- QYNMAEOUALQQAQ-LLVKDONJSA-N tert-butyl 6-amino-9-[(2R)-3-diethoxyphosphoryl-2-hydroxypropyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)C[C@H](CP(=O)(OCC)OCC)O)N QYNMAEOUALQQAQ-LLVKDONJSA-N 0.000 description 1
- NNNGRHMIUNBXRE-LLVKDONJSA-N tert-butyl 6-amino-9-[(2R)-4-diethoxyphosphoryl-2-hydroxybutyl]-2-fluoropurine-8-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1N(C2=NC(=NC(=C2N=1)N)F)C[C@@H](CCP(=O)(OCC)OCC)O NNNGRHMIUNBXRE-LLVKDONJSA-N 0.000 description 1
- CMSLOXGPSHQJHT-GFCCVEGCSA-N tert-butyl 6-amino-9-[(2R)-4-diethoxyphosphoryl-2-hydroxybutyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)C[C@@H](CCP(=O)(OCC)OCC)O)N CMSLOXGPSHQJHT-GFCCVEGCSA-N 0.000 description 1
- QYNMAEOUALQQAQ-NSHDSACASA-N tert-butyl 6-amino-9-[(2S)-3-diethoxyphosphoryl-2-hydroxypropyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)C[C@@H](CP(=O)(OCC)OCC)O)N QYNMAEOUALQQAQ-NSHDSACASA-N 0.000 description 1
- CMSLOXGPSHQJHT-LBPRGKRZSA-N tert-butyl 6-amino-9-[(2S)-4-diethoxyphosphoryl-2-hydroxybutyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)C[C@H](CCP(=O)(OCC)OCC)O)N CMSLOXGPSHQJHT-LBPRGKRZSA-N 0.000 description 1
- UMLGNSNPAQBPQT-MRVPVSSYSA-N tert-butyl 6-amino-9-[2-[(2R)-oxiran-2-yl]ethyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)CC[C@H]1OC1)N UMLGNSNPAQBPQT-MRVPVSSYSA-N 0.000 description 1
- UMLGNSNPAQBPQT-QMMMGPOBSA-N tert-butyl 6-amino-9-[2-[(2S)-oxiran-2-yl]ethyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)CC[C@@H]1OC1)N UMLGNSNPAQBPQT-QMMMGPOBSA-N 0.000 description 1
- ZMJODDGCDKBQHR-SSDOTTSWSA-N tert-butyl 6-amino-9-[[(2R)-oxiran-2-yl]methyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)C[C@H]1OC1)N ZMJODDGCDKBQHR-SSDOTTSWSA-N 0.000 description 1
- ZMJODDGCDKBQHR-ZETCQYMHSA-N tert-butyl 6-amino-9-[[(2S)-oxiran-2-yl]methyl]purine-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)C1=NC(=C2N=CN(C2=N1)C[C@@H]1OC1)N ZMJODDGCDKBQHR-ZETCQYMHSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Phosphonate acyclonucleosides their prodrugs, and their use as medicaments
- the present invention is in the field of chemical compounds belonging to the group of nucleotide analogs.
- the subject of the invention is phosphonate acyclonucleoside compounds as well as their method of preparation and their use as medicaments, in particular for the prevention and / or the treatment of diseases caused by an infection by an auxotrophic organism for purines such as Plasmodium falciparum .
- the invention also relates to pharmaceutical compositions comprising such compounds.
- nucleotide analogues in particular phosphonate acyclonucleosides, abbreviated as "ANP"
- ANP phosphonate acyclonucleosides
- the article by Kaiser et al. (Chem Chem Med Oct Oct 10 (10): 1707-23; 2015) describes the activity of ANPs inhibitors of P. falciparum 6-oxopurine PhosphoRibosyl Transferase (PRT).
- the ANPs described contain, as acyclic part, in particular (S) -2- (phosphonomethoxy) propanoic acid or (S) -2 -acidic acid.
- Phosphonoethoxy propanoic acid that is to say that the chain of atoms linking the nucleobase (or nucleobase) and the phosphonate group comprises an oxygen atom. Ki observed for some of these compounds on the activity of human hypoxanthine-guanine PhosphoRibosylTransferase (HGPRT) and hypoxanthine-guanine-xanthine Phospho-RibosylTransferase of Plasmodium falciparum (PfHGXPRT) are of the order of one micromolar.
- HGPRT human hypoxanthine-guanine PhosphoRibosylTransferase
- PfHGXPRT hypoxanthine-guanine-xanthine Phospho-RibosylTransferase of Plasmodium falciparum
- the lowest inhibitory concentration of 50% of the growth of strains of Plasmodium falciparum is observed for a prodrug form of the compound and is of the order of 20 ⁇ .
- Hockova et al. ⁇ Chem. Med. Chem. Oct; 10 (10): 1707-23; 2015) describes the activity of AN Ps inhibitors of 6-oxopurine PhosphoRibosyl Transferase (PRT) of P. falciparum.
- PRT 6-oxopurine PhosphoRibosyl Transferase
- the compounds described are aza-AN Ps, the chain of atoms linking the nucleobase (or nucleobase) and the phosphonate group having a nitrogen atom.
- Ai represents an adenine or a cytosine
- Rm represents a hydroxyl group, -ONa group, -O-methyl group or -O-ethyl group.
- the article by Kasthuri et al. (Tetrahedron: Assymetry, 22, 1505-11, 2011) describes the synthesis and characterization of structural analogues of the antiviral Adefovir (PM EA), used in the treatment of H BV infections. In vitro tests, in the presence of different viruses, show the absence of antiviral and cytotoxic activity of the compounds.
- PM EA antiviral Adefovir
- Hazelton et al. (Chem Biol 2012 Jun 22; 19 (6): 721-30, 2012) describe the activity of compounds belonging to the class of acyclic phosphonate immucillin, whose structure is characterized by the presence of a zapuric base and a nitrogen atom in the chain of atoms linking said base and the phosphonate group.
- the compounds according to the invention inhibit the growth of the parasite, the inhibitory concentration of 50% of the growth being of the order of nanomolar.
- the subject of the invention is therefore the compounds of general formula (I) below:
- A represents either a heterocycle of formula (IIA) or a heterocycle of formula (IIB) as follows:
- Wi represents an oxygen atom or a sulfur atom
- W2 represents a halogen atom, a group -OR5, a group -SR5, a group -N H (Rs) or a group -N (Rs) 2;
- X1 represents a nitrogen atom or a group -CH-;
- X3 represents a nitrogen atom or a -CH- group
- o be a hydrogen atom
- o is a group chosen from:
- R2 represents:
- o be a hydrogen atom
- o is a group chosen from:
- R 3 and R 4 identical or different, each represent, independently of one another:
- R5 represents:
- said groups optionally containing one or more heteroatoms
- R6 represents:
- o is a hydrogen atom, a sodium atom or a lithium atom, o is a group chosen from an ammonium group, or a group - N (R a RbRcRd) + with R a , Rt>, Rc and Rd identical or different ones each representing a hydrogen atom or an alkyl group
- o is a group chosen from:
- an S- (C 1 -C 12) alkyl-2-dithioethyl group said alkyl group optionally comprising at least one heteroatom
- acyl-2-thioethyl group an S- (C 1 -C 6) acyl-2-thioethyl group, said acyl group optionally comprising at least one heteroatom,
- R7 represents:
- o is an aryl group
- n is an integer equal to 0, 1 or 2;
- Y represents a substituent chosen from: a halogen atom, a group - OR 5, a group --SR 5, a group - NH (R 5) and a group - N (R 5) 2;
- C * represents a chiral carbon atom,
- the subject of the invention is the compounds of formula (I) as such, or their salts and stereoisomers, with the exception of the compounds of formula (I) in which:
- W2 represents the group - NH2
- Xi represents a nitrogen atom
- X 2 represents a group -CR 1 in which R 1 represents a hydrogen atom
- X3 represents a nitrogen atom
- X 4 represents a group -CR2 in which R2 represents a hydrogen atom
- n 1;
- Y is a hydroxy group or a group -N H2;
- the chiral carbon C * is of R or S configuration
- R 3 and R 4 each represents an -ORe group in which Re is a sodium atom.
- the subject of the invention is the compounds of formula (I) as such, or their salts and stereoisomers, with the exception of the compounds of formula (I) in which:
- W2 represents the group - NH2
- Xi represents a nitrogen atom
- X 2 represents a group -CR 1 in which R 1 represents a hydrogen atom
- X 4 represents a group -CR2 in which R2 represents a hydrogen atom
- n 1;
- Y represents a hydroxyl group or a group -N H2;
- the chiral carbon C * is of R or S configuration
- R 3 and R 4 each represent a group -ORe in which Rs is a sodium atom
- the subject of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising as active principle a compound of formula (I), with the exception of the compounds of formula (I) in which:
- - W 2 represents the group -N H2;
- Xi represents a nitrogen atom
- X 2 represents a group -CR 1 in which R 1 represents a hydrogen atom
- X3 represents a nitrogen atom
- X 4 represents a group -CR2 in which R2 represents a hydrogen atom
- n 1;
- Y represents a hydroxyl group or a glycan pe - N H2;
- the chiral carbon C * is of R or S configuration
- R3 and R4 each represent a group -ORe wherein Rs is a sodium atom
- the present invention firstly provides compounds of general formula (I) below:
- A represents either a heterocycle of formula (IIA) or a heterocycle of formula (IIB) as follows:
- Wi represents an oxygen atom or a sulfur atom
- NZ represents a halogen atom, a group -ORs, a group -SR5, a group -NHR5 or a group -N (Rs) 2;
- - X represents a nitrogen atom or a group -CH-;
- X3 represents a nitrogen atom or a -CH- group
- o be a hydrogen atom
- o is a group chosen from:
- R2 represents:
- o be a hydrogen atom
- o is a group chosen from:
- o is a group -N H R7
- o is a group -N (R7) 2;
- R5 represents:
- o is a hydrogen atom, a sodium atom or a lithium atom
- o is a group chosen from an ammonium group or a group - N (R a RbRcRd) + with R a , Rt>, Rc and Rd identical or different, each representing a hydrogen atom or an alkyl group
- an S- (C 1 -C 12) alkyl-2-dithioethyl group said alkyl group optionally comprising at least one heteroatom
- acyl-2-thioethyl group an S- (C 1 -C 6) acyl-2-thioethyl group, said acyl group optionally comprising at least one heteroatom,
- R7 represents:
- n is an integer equal to 0, 1 or 2;
- Y represents a substituent chosen from: a halogen atom, a group - OR5, a group -SR5, a group -NH (Rs) and a group -N (Rs) 2;
- heteroatom refers to an atom of any known element with the exception of carbon and hydrogen.
- a heteroatom denotes a nitrogen, oxygen, sulfur or phosphorus atom.
- hydroxyl group is meant -OH.
- ammonium group refers to the group -NH 4 + .
- the groups -N (RaRbRcRd) + may be secondary ammoniums, for example -NH2 (Et) 2 + or -NH2 (Et) 2 + , tertiary, for example -NH (Et) 3 + or -NH ( Me) 3 + , or quaternary as for example -N (Bu) 4 +
- the term "C 1 -C 12 alkyl group” means a linear, branched or cyclic, monovalent hydrocarbon-based chain containing from 1 to 12 carbon atoms, that is to say having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 carbon atoms.
- O-C6 alkyl group thus denotes an alkyl group having 1 to 6 carbon atoms and "C 1 -C 4 alkyl group” thus denotes an alkyl group having 1 to 4 carbon atoms.
- said alkyl group is linear. There may be mentioned by way of example, methyl, ethyl, n-propyl, isoproppyle, butyl, n-butyl, isobutyl, tert ⁇ io Buyle, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl and dodecyl or allyl.
- O2-C20 alkyl group is meant an alkyl group of 12 to 20 carbon atoms, i.e. having 12, 13, 14, 15, 16, 17, 18, 19 or 20 carbon atoms. carbon.
- said carbon chain may comprise at least one heteroatom and / or one or more double bonds.
- C2-C6 alkenyl group is meant a hydrocarbon chain of 2 to 6 atoms
- C 2 -C 5 alkynyl group is meant a hydrocarbon chain of 2 to 6 carbon atoms, linear, branched or cyclic, comprising at least one triple bond between two carbon atoms.
- aryl (C 1 -C 6) alkyl group is meant an alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal hybrid carbon atom or sp, is replaced by an aryl group.
- aryl group Bn
- heteroaryl group is meant a 5- to 7-membered or 7 to 10-membered monocyclic heterocyclic aromatic ring which is composed of carbon atoms and 1 to 4 heteroatoms independently selected from the group consisting of N, O and S, and is aromatic.
- heteroaryl groups are indolyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, cinnolinyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl isothiazolyl, , isoxazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyrazolotriazinyl, pyridazinyl, pyridyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolyl, quinolyl, thiazolyl, thienyl and tetrazolyl group, said groups may
- heteroaryl (Ci-C6) alkyl group is meant a heteroaryl group as defined above and linked by a carbon atom or a heteroatom to a C 1 -C 6 alkyl chain as defined above.
- heterocycle is meant a five, six or seven membered ring which may contain one or more heteroatoms chosen from N, O or S.
- C2-C6 acyl group is meant a group comprising a saturated or unsaturated, linear, branched or cyclic monovalent hydrocarbon chain containing from 2 to 6 carbon atoms.
- CH3CO- group the CH3CH2CH2CO- group and the CeHsCO- group.
- S- (C 1 -C 12) alkyl-2-dithioethyl group is meant an alkyl group comprising from 1 to 12 carbon atoms as defined previously substituted by a dithioethyl group.
- (C1-C8) alkyloxycarbonyloxymethyl ester group is meant an alkyl group comprising from 1 to 6 carbon atoms as defined previously substituted with a group O-CO-O-CH2-.
- S- (C 1 -C 12) aryl-2-dithioethyl group is meant an aryl group as defined above, especially from 1 to 12 carbon atoms, substituted with an S-S- (CH 2 ) 2 - group.
- S- (C 1 -C 6) acyl-2-thioethyl or "SATE” group is meant an alkyl or aryl group comprising from 1 to 6 carbon atoms as defined previously substituted with a -CO-S- group ( CH2) 2; mention may be made, for example, of S-benzoyl-2-thioethyl.
- (C 1 -C 6) acyloxy (C 1 -C 6) alkyl ester group is meant an alkyl or aryl group comprising from 1 to 6 carbon atoms as defined previously substituted with a -CO-O-CH 2 - group.
- esters refers to carboxyl-containing compounds having been esterified with a carbon group, and of the formula RCOOR 'where R and R' are each independently of each other a C 1 -C 2 alkyl group, advantageously Ci-Ce or an aryl group as defined above.
- amino acid ester derivative an amino acid whose acid function has been substituted by a C 1 -C 12 alkyl, advantageously C 1 -C 6 alkyl or an aryl group as defined above.
- amino acid amide derivative denotes a compound formed either by an amino acid as defined above, the acid function of which is linked to a nitrogen atom and corresponding to the formula AACONH2, or to the formula AACONH- (Ci -C6) alkyl, or at AACON H-aryl formula, or by at least two amino acids (in this case we will have peptides).
- drug is meant a pharmacologically active compound of formula (I) in which R 3 and R 4 represent a group -ORs, with Re representing a hydrogen atom, a sodium atom, a lithium atom, an ammonium group or a group - N (RaRbR c Rd) + with R a , Rb, R c and Rd identical or different each representing a hydrogen atom or a C 1 -C 4 alkyl group.
- prodrug is meant a compound of formula (I) pharmacodynamically inert and capable of being transformed in vitro and / or in vivo into a pharmacologically active drug as defined above.
- a chiral or asymmetric atom denotes an atom, each of which substituents are of a different nature. More particularly, the chiral carbon designated "C *" in the compounds according to the present invention has four substituents of different nature.
- the groups R 3 and R 4 linked to the phosphorus of a compound according to the invention are different, said phosphorus atom is chiral.
- the various isomers of the compounds according to the invention that is to say the enantiomers, stereoisomers, rotamers, tautomers, diastereoisomers or racemates, are included in the scope of the present invention.
- Such isomers can be obtained in a substantially pure form, by implementing a synthetic route for controlling the stereochemistry of the compounds obtained or the chemical resolution and / or by the use of separation processes such as for example chromatography or recrystallization. All of these methods are well known to those skilled in the art.
- the compounds of formula (I) for their use according to the invention comprise a mixture of the stereoisomers of a compound according to the invention. More particularly, the compounds of formula (I) for their use according to the invention comprise a mixture of stereoisomers whose carbon C * is respectively of configuration R or of configuration S. Even more particularly, when the phosphorus of the compound is chiral, the compounds of formula (I) for their use according to the invention comprise a mixture of stereoisomers in which the carbon C * is respectively of configuration R or configuration S and / or a mixture of stereoisomers whose phosphorus is respectively of configuration R or configuration S. In such a mixture, for each of the chiral atoms, the respective proportions of the stereoisomers are preferably between 1/99 and 99/1.
- the compounds of formula (I) for their use according to the invention comprise a racemic mixture of stereoisomers of a compound according to the invention. More particularly, the compounds of formula (I) for their use according to the invention comprise a racemic mixture of stereoisomers whose carbon C * is respectively of configuration R or configuration S. When the phosphorus of the compound is chiral, the compounds of formula (I) for their use according to the invention comprise a racemic mixture of stereoisomers in which the carbon C * is respectively of configuration R or of configuration S and / or a racemic mixture of stereoisomers whose phosphorus is respectively of configuration R or configuration S .
- the compounds of formula (I) for their use according to the invention comprise a mixture of stereoisomers whose carbon C * is respectively of configuration R or of configuration S and whose the phosphorus is respectively R configuration or S configuration.
- the compounds of formula (I) for their use according to the invention comprise the pure enantiomer of the compound in which the carbon C * is of configuration R. According to another particular aspect of the invention, According to the invention, the compounds of formula (I) for their use according to the invention comprise the pure enantiomer of the compound in which the carbon C * is of S configuration.
- the synthetic route used to prepare the compounds according to the invention makes it possible to control the stereochemistry of any other asymmetric atoms of the compounds, such as, for example, the phosphorus atom of the phosphonate group. or one or more carbon of a carbon group of a compound, especially an amino acid derivative.
- the compounds according to the invention can be obtained by synthesis steps well known to those skilled in the art, and from compounds available commercially and inexpensively.
- the stereochemistry of the final molecules comes from the chirality of the amino acids used for synthesis (aspartic acid) and is controlled throughout the synthesis.
- - W 2 represents a group -O (Rs) in which Rs represents an alkyl group
- - W 2 represents a group -S (Rs) in which Rs represents a C 1 -C 6 alkyl group, or
- - W 2 represents a group -N (Rs) 2 in which Rs represents a C 1 -C 6 alkyl group, or
- W 2 represents a group -NH (Rs) in which Rs represents a C 1 -C 6 alkyl group, or
- W 2 is -NH (Rs), -N (Rs) 2, or -NH 2 ;
- - Xi represents a nitrogen atom
- X 2 represents a group -CH
- - X 4 represents a group -CH.
- the compounds of formula (I) for their use according to the invention are characterized in that Y represents a group -ORs, with Rs representing: a hydrogen atom, a C 1 -C 6 alkyl group, an alkenyl group C2-C6, C2-C6 alkynyl, aryl, C1-C6 acyl or aryl (C1-C6) alkyl.
- R5 represents a methyl, ethyl, benzyl, propargyl, allyl or cyanomethyl group.
- the compounds of formula (I) for their use according to the invention have one of the following structural characteristics:
- R 4 represent a hydroxyl group
- R4 represent a group -ORe in which Re represents a sodium atom or a lithium atom.
- the compounds of formula (I) for their use according to the invention have one of the following structural characteristics:
- R3 represents a group -ORe and R4 represents a group -NH R7;
- R3 represents a group -ORe and R4 represents a group -N (R7) 2;
- R 3 and R 4 are -NH R7.
- the subject of the invention is the compounds of formula (I) in which A represents a purine chosen from: guanine, xanthine, hypoxanthine, adenine and 2,6-diaminopurine, for their use according to the present invention.
- A represents a purine chosen from: guanine, xanthine, hypoxanthine, adenine and 2,6-diaminopurine, for their use according to the present invention.
- Wi represents an oxygen atom
- - Xi represents a nitrogen atom
- X 2 is -CR 1, R 1 is hydrogen;
- X3 represents a nitrogen atom
- X 4 represents a group -CR2 with R2 representing a group -NH2.
- xanthine corresponds to a heterocycle of formula (IIA) in which:
- Wi represents an oxygen atom
- Xi represents a nitrogen atom
- X 2 is -CR 1, R 1 is hydrogen;
- X3 represents a nitrogen atom
- hypoxanthine corresponds to a heterocycle of formula (IIA) in which: Wi represents an oxygen atom;
- Xi represents a nitrogen atom
- Xi represents a group -CRi, Ri representing a hydrogen atom
- X 4 represents a group -CR2 with R2 representing a hydrogen atom.
- W2 is -NH2
- - Xi represents a nitrogen atom
- X 2 is -CR 1, R 1 is hydrogen;
- X3 represents a nitrogen atom
- X 4 represents a group -CR2 with R2 representing a hydrogen atom.
- R2 representing a hydrogen atom.
- 2,6-diaminopurine corresponds to a heterocycle of formula (IIB) in which:
- W2 is -NH2
- Xi represents a nitrogen atom
- X 2 is -CR 1, R 1 is hydrogen;
- X 4 represents a group -CR2 with R2 representing a group -NH2.
- n is equal to 0, 1 or 2; the carbon chain between the heterocycles and the phosphonate group then comprises, respectively, 3, 4 or 5 carbon atoms. More particularly, there may be mentioned compounds of formula (I) in which n is equal to 1.
- A represents guanine, xanthine or hypoxanthine, and more particularly guanine, and n is equal to 0. , 1 or 2, and more particularly n is 1.
- A represents adenine or 2,6-diaminopurine, and more particularly 2,6-diaminopurine, and n is equal to 0, 1 or 2, and more particularly n is equal to 1.
- the compounds of formula (I) for their use according to the present invention there may be mentioned compounds in which Y represents the hydroxyl group.
- the compounds of formula (I) for their use according to the present invention there may be mentioned compounds in which Y represents a hydrogen atom or a group -N H2. More particularly, among the compounds of formula (I) for their use according to the present invention, mention may be made of the compounds in which A represents guanine, xanthine or hypoxanthine, n is equal to 0, 1 or 2, and Y represents the hydroxyl group.
- R 3 and R 4 each represent a group -ORe and Re represents a hydrogen atom, an atom of sodium, a lithium atom, an ammonium group or a group - N (R a RbR c Rd) + with R a , Rb, Rc and Rd identical or different, each representing a hydrogen atom or a C1-C6 alkyl group C4.
- Said compounds represent the "drug" form of said compound.
- R 3 and R 4 which are identical or different, each represent, independently of one another, either a group -ORe, or a group -NH R7 OR a group -N (R7) 2; with Re representative:
- An S- (C 1 -C 12) alkyl-2-dithioethyl (or DTE) group said alkyl group possibly comprising at least one heteroatom
- a C12-C20 alkyl group optionally comprising at least one heteroatom, especially an oxygen atom,
- R7 represents:
- said groups represented by Re or R7 constituting groups protecting the phosphonate functions are intended to facilitate the passage of the compounds according to the invention through a biological membrane, in particular the membrane of the intestinal epithelium or a cell membrane, after the administration in vivo and before entry. in the target cell.
- a protecting group therefore influences the lipophilicity of the compound as well as its kinetics of degradation.
- ORe and Re represents a sodium atom
- A represents 2,6-diaminopurine
- n is 1
- Y represents a hydroxyl group
- the chiral carbon C * is of configuration R, f3 ⁇ 4 and R 4 each represent a group
- the term "pharmaceutically acceptable” means any ingredient which is useful in the preparation of a pharmaceutical composition which is generally safe, non-toxic, and neither biologically nor otherwise undesirable and which is acceptable for veterinary use or for use in veterinary medicine. 'Man.
- pharmaceutically acceptable salts of a compound means salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity of the parent compound. Such salts include:
- pharmaceutically acceptable acid addition salts formed with pharmaceutically acceptable inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or formed with pharmaceutically acceptable organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fumaric acid, acid glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, hydroxynaphthoic acid, 2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, muconic acid, 2-naphthalenesulfonic acid, propionic acid, salicylic acid, succinic acid, dibenzoyl-L-tartaric acid, tartaric acid, p-acid, toluenesulphonic acid, trimethylacetic acid, trifluoroacetic
- compositions formed when an acidic proton present in the parent compound is either replaced by a metal ion, for example an alkali metal ion, an alkaline earth metal ion or a aluminum, a sodium ion or a lithium ion; is coordinated with a pharmaceutically acceptable organic or inorganic base.
- Acceptable organic bases include diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine and the like.
- Acceptable inorganic bases include aluminum salts, including aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.
- auxotrophic organism for purines means a living organism which does not have a pathway for the de novo synthesis of purines nucleoside monophosphates, or which does not substantially have such a biosynthetic pathway. While mammalian cells are capable of producing purines nucleoside monophosphates by de novo synthesis, on the one hand, and by recovery of the preformed purine bases, on the other hand, said auxotrophic organisms for purines depend on the recovery of the six oxo-purines from the host cell, including the recovery of hypoxanthine.
- HG (X) PRT Hydrophilicity-reduction reaction
- HG (X) PRT Hydrophilicity-reduction reaction
- said auxotrophic organism for purines is a microorganism chosen from bacteria and protozoa.
- said auxotrophic organism for purines is chosen from the following: - Plasmodium spp. , causative agents of paludism, particularly Plasmodium falciparum, Plasmodium vivax, Palasmodium malahae, Plasmodium ovale, Plasmodium knowlesi,
- the invention relates to a compound according to the invention for its use in the prevention and / or treatment of an infection with an agent chosen from: Plasmodium falciparum, Plasmodium vivax, Palasmodium mala ae , Plasmodium ovale or Plasmodium knowlesi, and more particularly the prevention and / or treatment of a Plasmodium falciparum infection.
- an agent chosen from: Plasmodium falciparum, Plasmodium vivax, Palasmodium mala ae , Plasmodium ovale or Plasmodium knowlesi, and more particularly the prevention and / or treatment of a Plasmodium falciparum infection.
- the subject of the invention is a compound according to the invention for its use in the prevention and / or treatment of malaria, caused by infection with Plasmodium falciparum.
- the subject of the invention is a compound according to the invention for its use in the prevention and / or the treatment of uncomplicated malaria, orally, as a first intention.
- the subject of the invention is a compound according to the invention for its use in the prevention and / or the treatment of a pathology caused by an infection with Toxoplasma, in particular Toxoplasma gondii.
- the subject of the invention is the compounds of formula (I), their salts and stereoisomers, with the exception of compounds in which:
- - W2 represents the group-Nhh
- - Xi represents a nitrogen atom
- X 2 represents a group -CR 1 in which R 1 represents a hydrogen atom
- - X3 represents a nitrogen atom
- X 4 represents a group -CR 2 in which R 2 represents a hydrogen atom
- n 1;
- Y represents a group chosen from: a hydroxyl group and a group - the chiral carbon C * is of R or S configuration
- R 3 and R 4 are the same and each represent a group - OR e and R e represents a hydrogen atom, a sodium atom, methyl or ethyl.
- the subject of the invention is therefore the compounds of formula (I), their salts and stereoisomers, with the exception of compounds in which A represents an adenine and in which n is equal to 1; Y represents a group selected from: a hydroxyl group and a group - N H2; the chiral carbon C * is R or S configuration, and R 3 and R 4 are the same and each represent a group - OR e and - Re represents a hydrogen atom, a sodium atom, methyl or ethyl.
- the subject of the invention is compounds of formula (I) characterized in that A represents a 6-oxo-purine chosen from guanine, xanthine and hypoxanthine, and even more particularly A represents guanine.
- the subject of the invention is compounds of formula (I) characterized in that A represents a 6-amino-purine chosen from adenine and 2,6-diaminopurine with the exception of compounds in which:
- n 1;
- Y is a group selected from: a hydroxyl group and an --NH 2 group ;
- the chiral carbon C * is of R or S configuration
- R 3 and R 4 are the same and each represent a group - OR e and R e represents a hydrogen atom, a sodium atom, methyl or ethyl.
- the subject of the invention is compounds of formula (I) in which A represents 2,6-diaminopurine.
- the subject of the invention is compounds of formula (I) in which A represents guanine, xanthine, hypoxanthine or 2,6-diaminopurine and that:
- n 1 and / or
- Y represents a hydroxyl group and / or
- R 3 and R 4 each represent a -OR6 and R6 represents a hydrogen atom or a sodium atom or lithium atom.
- the subject of the invention is compounds of formula (I) in which A represents guanine, n is an integer equal to 1 and Y represents a hydroxyl group, and more particularly R 3 and R 4 each represent a group.
- - OR6 and R6 represents a hydrogen atom, a sodium atom or a lithium atom.
- the subject of the invention is compounds of formula (I) in which A represents 2,6-diaminopurine, n is an integer equal to 1 and Y represents a hydroxyl group, and more particularly R 3 and R 4 are each -ORe and Re is hydrogen, sodium or lithium.
- - A represents guanine, n is 1, Y represents a hydroxyl group, the chiral carbon C * is R configuration, and R 3 and R 4 each represents an -ORe group and -OR e represents a sodium atom;
- - A represents guanine, n is 1, Y represents a hydroxyl group, the chiral carbon C * is R configuration, R 3 and R 4 each represents an -ORe group and -OR e represents a PheSATE group;
- A represents 2,6-diaminopurine, n is 1, Y represents a hydroxyl group, the chiral carbon C * is of R configuration, and R 3 and R 4 each represent a group - ORe and Re represents an atom. sodium;
- - A represents 2,6-diaminopurine
- n is 1
- Y represents a hydroxyl group
- the chiral carbon C * is of S configuration
- R 3 and R 4 each represent a group - OR e and R e represents a sodium atom ;
- - A represents guanine
- n is 1
- Y represents a hydroxyl group
- the chiral carbon C * is of S configuration
- R 3 and R 4 each represents an -ORe group and Re represents a sodium atom.
- the subject of the invention is the compounds of formula (I), their salts and stereoisomers, with the exception of compounds in which:
- - W2 represents the group-Nhh
- - Xi represents a nitrogen atom
- X 2 represents a group -CR 1 in which R 1 represents a hydrogen atom
- X 4 represents a group -CR 2 in which R 2 represents a hydrogen atom
- n 1;
- Y represents a group selected from: a hydroxyl group and a group - N H2;
- the chiral carbon C * is of R or S configuration
- R 3 and R 4 are the same and each represents an -ORe group and Re represents a hydrogen atom, a sodium atom, a methyl group or an ethyl group,
- the present invention relates to compounds of general formula (I) or its pharmaceutically acceptable salts and stereoisomers, for their use as a medicament for the prevention and / or treatment an infection with an auxotrophic organism for purines, and in particular infection with Plasmodium spp.
- the subject of the invention is also compounds according to the invention intended to be used as a medicament.
- the subject of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising, as active agent, a compound of formula (I), with the exception of compounds in which:
- - W 2 represents the group -NH 2 ;
- - Xi represents a nitrogen atom
- X 2 represents a group -CR 1 in which R 1 represents a hydrogen atom
- X 4 represents a group -CR 2 in which R 2 represents a hydrogen atom
- n 1;
- Y is a group selected from: a hydroxyl group and an --NH 2 group ;
- the chiral carbon C * is of R or S configuration
- R 3 and R 4 are the same and each represents an -ORe group and Re represents a hydrogen atom, a sodium atom, methyl or ethyl.
- a pharmaceutical composition according to the invention comprises at least one compound according to the invention, and at least one pharmaceutically acceptable excipient.
- pharmaceutically acceptable excipient any substance other than the active ingredient, intended to provide consistency, taste, color to a drug, while avoiding any interaction with the active ingredient.
- the pharmaceutically acceptable excipient according to the invention will be chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art, for administration to humans or animals. .
- the modes of administration, the dosages and the optimal dosage forms of a pharmaceutical composition according to the invention can be determined according to the criteria generally taken into account in the establishment of a pharmaceutical treatment adapted to a subject such as the age or the body weight of the patient, the severity of his general condition, the tolerance to treatment, the side effects noted.
- the pharmaceutical composition according to the invention may further comprise at least one pharmaceutically acceptable excipient.
- the pharmaceutical composition according to the present invention may further comprise at least one adjuvant pharmaceutically known to a person skilled in the art, chosen from thickeners, preservatives, perfumes, dyes, chemical or mineral filters, moisturizing agents, water thermal baths, etc.
- oral administration is recommended. Suitable forms of administration will include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual and oral forms of administration.
- the subject of the invention is also a pharmaceutical composition according to the invention for its use in the prevention and / or treatment of a disease caused by an infection by an auxotrophic organism for purines, said organism being selected from bacteria and protozoa, including malaria, caused by infection with Plasmodium falciparum.
- the subject of the invention is also a method of preventing and / or treating an infection caused by an auxotrophic organism for purines, characterized in that it comprises the administration to a subject having need a compound of formula (I).
- the method of prevention and / or treatment according to the invention is characterized in that said subject is a human being or an animal.
- a method of prevention and / or treatment according to the invention is particularly applicable to a subject suffering from malaria.
- FIGS. 1A to 1C show a representative image of the experimental results of the detection of the anti-toxoplasmosis activity in vitro of various compounds; Compounds No. 3 (Fig. 1A), 5 (Fig. 1B) and 15 (Fig. 1C) are added respectively at concentrations of 5 ⁇ (central column) and 50 ⁇ (right column) at a monolayer of fibroblasts.
- the purine nucleobases are deaminated according to the procedures described in the literature to yield compounds of formulas VII from the compounds of formula VI.
- the protecting groups of the phosphonate function are removed according to the procedures described in the literature to yield compounds of formula V from compounds of formula IV and compounds of formula VIII from compounds of formula VII.
- the birds are removed under reduced pressure and the residue is taken up in ethyl ether, after overnight at 4 ° C, the solid is removed.
- the filtrate is concentrated and purified on a column of silica gel (ChhC / MeOH, 0-5% or isocratic AcOEt) to conduct after evaporation of the combined fractions to the expected compound (formula III).
- N 2 , N 2 -Bis (tert-butoxycarbonyl) -6-O-methyl-9 - ⁇ [(2R) -oxiran-2-yl] ethyl ⁇ 2-aminopurine: Yield 79%; colorless oil; (CH 2 Cl 2 / MeOH, 95/5, v / v);
- N 2 , N 2 -Bis (tert-butoxycarbonyl) -6-O-methyl-9 - ⁇ [(2S) -oxiran-2-yl] ethyl ⁇ 2 -aminopurine yield 78%; colorless oil; (CI-hC / MeOH, 95/5, v / v);
- N 6 , N 6 -Bis (tert-butoxycarbonyl) -9 - [(2S) -2-hydroxy-3-diethylphosphonopropyl] adenine, yield 64.2%; white solid; (CH 2 Cl 2 / MeOH, 90/10, v / v);
- N 6 , N 6 -Bis (tert-butoxycarbonyl) -9 - [(2R) -2-hydroxy-4-diethylphosphonobutyl] adenine: Yield 68%; white solid; (ChhCl / MeOH, 95/5, v / v);
- N 6 , N 6 -Bis (tert-butoxycarbonyl) -9 - [(2S) -2-hydroxy-4-diethylphosphonobutyl] adenine: Yield 69%; white solid; (ChhCl / MeOH, 95/5, v / v);
- reaction medium is then concentrated under reduced pressure and the residue is purified on a reverse phase silica gel column (H 2 O / MeOH, 0-100%) to conduct, after evaporation of the collected fractions and lyophilization of the residue, the expected compound of formula VII.
- Detection of anti-Plasmodium falciparum activity in vitro Measurement of antimalarial activity involves contacting Plasmodium falciparum-infected erythrocytes (strain 3D7) with variable concentrations of test compound for 48 h (the duration of a cycle in P. falciparum).
- the culture conditions are 1.5% hematocrit and 0.6% initial parasitaemia in complete medium (RPMI 1640 + 10% human serum AB + + gentamycin).
- the viability of the parasite is measured by its ability to synthesize nucleic acids from a radioactive precursor, [ 3 H] -hypoxanthine or 3 H-ethanolamine.
- the radioactive precursor is added and the reaction is continued for 18 h and then frozen by stopping at -80 ° C.
- Macromolecules, including nucleic acids radiolabeled, are collected on a filter. The incorporated radioactivity is measured by scintillation counter after addition of scintillation cocktail.
- the radioactive background is measured from a suspension of healthy erythrocytes (same conditions as parasitized suspensions). The viability of the parasites is expressed as a percentage of the control (non-specific deduced). The measurements are analyzed using Excel and Prism software and the IC50 (concentration capable of inhibiting in vitro 50% of parasite growth) is determined graphically. The IC50s thus determined are the result of at least two experiments carried out independently in duplicate. The results obtained are detailed in Table 2 below. Lots A and B correspond to two different syntheses according to the same process and carried out in their entirety by two different manipulators, six months apart.
- Suspensions of human cells are cultured in complete RPMI medium (RPMI 1640 medium, L-glutamine, penicillin / streptomycin and 10% fetal calf serum) (200 ⁇ l), ie in the absence of the test compound. (controls), or in contact with varying concentrations of said compound.
- complete RPMI medium RPMI 1640 medium, L-glutamine, penicillin / streptomycin and 10% fetal calf serum
- the radioactive background is measured from complete RPMI medium.
- the viability of the cells is expressed as a percentage of the control (non-specific deduced).
- the measurements are analyzed using Excel and Prism software and the IC50 (concentration capable of inhibiting in vitro 50% of cell growth) is determined graphically.
- the IC50s thus determined are the result of at least two experiments carried out independently in duplicate. The results obtained are detailed in Table 2 above. 2.2. Detection of anti-Babesia divergens activity in vitro
- the activity of compounds against the growth of Babesia divergens is measured by bringing Babesia divergens-infected erythrocytes into contact with varying concentrations of the test compound for 16 h (the two-cycle duration in B. divergens).
- the culture conditions are 1.5% hematocrit and 0.6% initial parasitaemia in complete medium (RPMI 1640 + 10% human serum AB + + gentamycin).
- the viability of the parasite is measured by its ability to synthesize nucleic acids from a radioactive precursor, [ 3 H] -hypoxanthine.
- the radioactive precursor is added and the reaction is continued for 8 h and then frozen by stopping at -80 ° C.
- macromolecules including radiolabeled nucleic acids, are collected on a filter. The incorporated radioactivity is measured by scintillation counter after addition of scintillation cocktail.
- the radioactive background is measured from a suspension of healthy erythrocytes (same conditions as parasitized suspensions). The viability of the parasites is expressed as a percentage of the control (non-specific deduced). The measurements are analyzed using Excel and Prism software and the IC50 (concentration capable of inhibiting in vitro 50% of parasite growth) is determined graphically.
- Detection of anti-Toxoplasmosis activity in vitro by "plate assay” This test is based on the ability of Toxoplasma gondii in its intracellular form (tachyzoite) to lyse its host cell (in this case a monolayer of fibroblasts) and then to infect the cells. Neighboring cells so that over time (days) a macroscopically visible hole in the cell monolayer becomes apparent and its area can be measured. In 24-well culture plates, about 80 parasites are added to a monolayer of fibroblasts (HFF cells) for 7 days in the presence or absence of drugs. The cells are then fixed with 4% paraformaldehyde and then stained with Giemsa.
- HFF cells monolayer of fibroblasts
- the cells are visualized under a microscope and the size of the lysis plates is measured using a Zen® (Zeiss) log.
- the cells are maintained in culture in complete medium (DM EM + 5% fetal calf serum + glutamine + penicillin / streptomycin).
- complete medium DM EM + 5% fetal calf serum + glutamine + penicillin / streptomycin.
- the ability of the drug to inhibit the growth of Toxoplasma gondii is proportional to the decrease in the size of the plaque of lysis.
- the "drug" compounds Nos. 3, 5, 8 and 15 show a good in vitro activity against P. falciparum with ICso values of less than 50 ⁇ l and to a lesser extent compound 16 with IC50 values of less than 100 ⁇ l.
- Compound 5 is the best candidate with nanomolar activity.
- Compounds 3 and 5 are also active in the same concentration range against Babesia divergens.
- Prodrug compounds Nos. 4 and 6 show good activity against P. falciparum (of the order of one micromolar) but no selectivity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1752405A FR3064268A1 (en) | 2017-03-23 | 2017-03-23 | ACYCLONUCLEOSIDES PHOSPHONATES, THEIR PRODUCTS, AND THEIR USE AS MEDICAMENTS. |
PCT/EP2018/057219 WO2018172435A1 (en) | 2017-03-23 | 2018-03-21 | Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3601302A1 true EP3601302A1 (en) | 2020-02-05 |
Family
ID=59859137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18717242.4A Withdrawn EP3601302A1 (en) | 2017-03-23 | 2018-03-21 | Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament |
Country Status (7)
Country | Link |
---|---|
US (1) | US11299506B2 (en) |
EP (1) | EP3601302A1 (en) |
CN (1) | CN110461858A (en) |
BR (1) | BR112019019736A2 (en) |
FR (1) | FR3064268A1 (en) |
WO (1) | WO2018172435A1 (en) |
ZA (1) | ZA201906271B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023525047A (en) | 2020-05-06 | 2023-06-14 | エイジャックス セラピューティクス, インコーポレイテッド | 6-heteroaryloxybenzimidazoles and azabenzimidazoles as JAK2 inhibitors |
CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0296589A (en) * | 1988-09-30 | 1990-04-09 | Asahi Glass Co Ltd | Nucleosides |
EP2847201B1 (en) * | 2012-05-07 | 2017-08-16 | The University of Queensland | 6-oxopurine phosphoribosyltransferase inhibitors |
-
2017
- 2017-03-23 FR FR1752405A patent/FR3064268A1/en not_active Withdrawn
-
2018
- 2018-03-21 WO PCT/EP2018/057219 patent/WO2018172435A1/en unknown
- 2018-03-21 US US16/496,888 patent/US11299506B2/en active Active
- 2018-03-21 EP EP18717242.4A patent/EP3601302A1/en not_active Withdrawn
- 2018-03-21 CN CN201880020241.9A patent/CN110461858A/en active Pending
- 2018-03-21 BR BR112019019736A patent/BR112019019736A2/en not_active Application Discontinuation
-
2019
- 2019-09-23 ZA ZA2019/06271A patent/ZA201906271B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110461858A (en) | 2019-11-15 |
US20200101091A1 (en) | 2020-04-02 |
BR112019019736A2 (en) | 2020-04-14 |
US11299506B2 (en) | 2022-04-12 |
ZA201906271B (en) | 2020-08-26 |
WO2018172435A1 (en) | 2018-09-27 |
FR3064268A1 (en) | 2018-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1024865B1 (en) | IMIDAZOQUINOLEINE DERIVATIVES | |
JP6177832B2 (en) | Arginase inhibitors and methods of use | |
TWI362934B (en) | Phosphonate analogs of hiv inhibitor compounds | |
EA019749B1 (en) | Antiviral compounds | |
JP2001511172A (en) | A compound constituting an effector of a central nervous system receptor particularly sensitive to a neurostimulant amino acid, its production and its biological use | |
EP2125803A1 (en) | Pyrrolo[2,3-b]pyridine compounds, azaindole compounds used for synthesizing said pyrrolo[2,3-b]pyridine compounds, methods for the production thereof, and uses thereof | |
EP3601302A1 (en) | Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament | |
WO2015197006A1 (en) | Substituted amino acid thioester compound, and composition and application thereof | |
EP2847201B1 (en) | 6-oxopurine phosphoribosyltransferase inhibitors | |
TW201902507A (en) | Combination therapy for treating viral infections | |
JP2015515496A (en) | Pantothenic acid derivatives for the treatment of disorders of the nervous system | |
FR2776660A1 (en) | DIAZEPINO-INDOLES OF IV PHOSPHODIESTERASES | |
FR2934266A1 (en) | NITROGEN DERIVATIVES OF PANCRATISTATIN | |
WO2007080324A2 (en) | Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof | |
JPH09508628A (en) | Method for producing HIV protease inhibitor | |
TW442469B (en) | Fibrinogen receptor antagonists having substituted β-amino acid residues and pharmaceutical compositions comprising the same | |
KR900006132B1 (en) | Gem - dihalo - 1,8 -diamino - 4- aza - octane | |
US8349834B2 (en) | Dioxolane derivates for the treatment of cancer | |
LU85607A1 (en) | DRUGS BASED ON 1,2-DITHIOLANE DERIVATIVES | |
JP4354016B2 (en) | Novel purine derivative and pharmaceutical composition containing the same | |
RU2665037C2 (en) | Isopropyl n-[{[(1r)-2-(6-amino-9h-purin-9-il)-1-methyletoxy]methyl} (1,3-benzotiazol-6-il-oxy)phosphoryl]-l-alaninate fumarat as an antiviral drug - prodrug of tenofovir | |
EP0315519B1 (en) | Aminopimelic acid derivatives, process for their preparation and their use as medicines | |
TW201708239A (en) | Substituted amino acid thioester compound, its composition and application specifically related to preparing the drugs for treating virus infectious diseases | |
KR101881115B1 (en) | Novel 2-substituted tetrahydropyran or 2-substituted tetrahydrofuran derivatives, method for preparing the same, and use thereof | |
WO2014027081A1 (en) | Trisubstituted pyrido[2,3-d]pyrimidines, methods for preparing same and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190925 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40015074 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20201112 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231003 |